Christel Iffland

Christel Iffland has extensive work experience in the field of antibody technologies. Christel is currently working at OmniAb, Inc. as the Sr Vice President of Antibody Technologies and Vice President of Antibody Technologies. Prior to that, they held the position of Vice President of Antibody Technologies at Ligand Pharmaceuticals from 2017 to 2022. Before joining Ligand Pharmaceuticals, Christel worked at EMD Serono, Inc. where they served as the Associate Director of Antibody Technologies and Group Leader of Antibody Screening. During their time at EMD Serono, they played a significant role in directing antibody discovery processes and establishing efficient evaluation processes for antibody hits. Christel also contributed to the technical assessment of new opportunities and facilitated the full access of the Omnirat technology to Merck/EMD Serono. Christel's earlier experience includes working as a Senior Scientist II in Phage Technology at EMD Serono and as a Senior Scientist I in New Technologies at EMD Serono (former EMD Lexigen). Christel conducted post-doctoral research at the Dana-Farber Cancer Institute and Albert Einstein College of Medicine of Yeshiva University, studying the regulation of c-Myc activity and developing knockout vector constructs. Christel also worked as a graduate student at INSERM, Nice.

Christel Iffland has a diverse education history. Christel obtained a Doctor of Philosophy (Ph.D.) degree in Transcription factors, oncology, and myelomonocytic differentiation from Université Côte d'Azur between 1994 and 1997. Prior to that, they completed a Master's Degree in Isolation and characterization of hamster PPARgamma from the same university from 1992 to 1993. As for their earlier education, there is no available information about any degrees or fields of study from Lycee Carnot. In terms of certifications, Christel obtained a PMP (Project Management Professional) certification from the Project Management Institute in December 2015.